According to previous studies on plasma cell dyscrasias (PCD) genomics, the most frequently occurring mutations involve members of the RAS/MAPK cell proliferation pathway (in up to 40% of cases) including KRAS, NRAS and BRAF [6, 16], and the NF-kB pathway comprising around 20% of all myeloma cases, with NFKB1, TRAF3, CYLD, LTB as the most frequently mutated genes [16, 17]. This evidence concerns the gene NFKB1 and plasma cell myeloma.